lidocaine / prilocaine
Fortacin is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration).
Fortacin contains the active substances lidocaine and prilocaine.
Fortacin : EPAR - Medicine overview (PDF/120.28 KB)
First published: 25/11/2013
Last updated: 19/10/2020
Fortacin : EPAR - Risk-management-plan summary (PDF/60.74 KB)
First published: 19/10/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Sexual Dysfunction, Physiological
|Anatomical therapeutic chemical (ATC) code||
Recordati Ireland Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
15/09/2023 Fortacin - EMEA/H/C/002693 - R/0038
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment of primary premature ejaculation in adult men.